PRESS RELEASE

Expiry of extended deadline for submitting lists for the appointment of the board of statutory auditors: no list filed

Milan (Italy), 28 March 2016 – With reference to the shareholders' meeting of MolMed S.p.A. (MLM.MI), convened for 18 April 2016 on single call to resolve, among other items, on the appointment of members of the board of statutory auditors, MolMed announces that, on expiry of the extended deadline of 27 march 2016 with minimum threshold necessary for the submission reduced by half, no list was filed.

Please note that, as reported in the press release of 25 March 2016, the lists (and related documentation) submitted by shareholder Fininvest S.p.A. - who certified the ownership of 25,43% of the ordinary shares of the Company, are available (in Italian) at the Company's registered office, in the storage system authorised by Consob 1Info (www.1info.it) and on MolMed's website (http://www.molmed.com) within the page devoted to the shareholders' meeting of 16 April 2016.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and secondary office at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa
Investor Relations Director
MolMed S.p.A.
telefono: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

FROM GENES TO THERAPY